Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
暂无分享,去创建一个
R. Greil | H. Ludwig | A. Weissmann | C. Leitgeb | H. Kasparu | W. Linkesch | N. Zojer | L. Pour | Z. Adam | A. Seebacher | E. Rauch